Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...

The most common cardiovascular killer in maternal medicine is also among the most misdiagnosed. Peripartum cardiomyopathy ...

"On the heels of Nimbl's launch for patients with upper extremity swelling, we are pleased to now expand access to the 16 ...

High Altitude Pulmonary Edema (HAPE) HAPE results from fluid buildup in the lungs ... Anyone suffering from HAPE must be evacuated to a medical facility for proper follow-up treatment. HACE is the ...

Finding it hard to breathe when you lay down is medically called orthopnea. Find a list of potential causes to help narrow ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Medical research on hypothermia and cold injuries is always changing knowledge and treatment. When going into cold conditions ... pulse may not be palpable 78º - 75ºF Pulmonary edema, cardiac and ...

The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release. The decision was ...

The diabetic macular edema market presents a robust competition and ongoing advancements in treatment modalities. With an increasing prevalence of diabetes worldwide, the demand for effective DME ...

Feb. 6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME) after studies showed that it could help maintain vision with as few as two ...